Page 56 - ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lexaria Provides Progress Report on Six R&D Programs ACCESSWIRE 09 Jun 2021, 21:05 GMT+10 All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine These studies are part of Lexaria s 2021 applied R&D program intended to enable opportunities for strategic partnerships KELOWNA, BC / ACCESSWIRE / June 9, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (the Company or Lexaria ), a global innovator in drug delivery platforms, provides this progress report on several studies within its 2021 applied research and development (R&D) program. Other studies actively underway and planned will be reported on separately. VIRAL-A20-2 - A tolerability and pharmacokinetic or PK study in animals using antiviral drugs remdesivir and ebastine.

British columbiaLexaria dehydraExchange commissionNuclear magnetic resonanceCanada national research councilLexaria bioscience corpCompany or lexariaDrug administrationLexaria bioscienceArea underNational researchUnited states wire groupபிரிட்டிஷ் கொலம்பியாபரிமாற்றம் தரகுஅணு காந்த அதிர்வுகனடா தேசிய ஆராய்ச்சி சபை